Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protein-bound uremic toxin lowering effects of sevelamer in end-stage kidney disease receiving hemodialysis with hyperphosphatemia
TCTR20230530004Phase 4Completed
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Jul 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of sevelamer carbonate in end-stage kidney disease (ESKD), hyperphosphatemia, sponsored by Faculty of Medicine, Chulalongkorn University. Started Jul 2023; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
end-stage kidney disease (ESKD)hyperphosphatemia
Beyond the preview
Go deeper on TCTR20230530004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230530004.